Jessica Hersh

Ms. Jessica Hersh

Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in ACS Applied Bio Materials
Verified
Journal Article
Open access
JHJessica Hersh
Jessica Hersh
DBDavid Broyles
David Broyles
JCJose Manuel Condor Capcha
Jose Manuel Condor Capcha
EDEmre Dikici
Emre Dikici
LSLina A Shehadeh
Lina A Shehadeh
SSSuresh Shrestha
Suresh Shrestha
Polymeric biomaterials have been used in a variety of applications, like cargo delivery and tissue scaffolding, because they are easily synthesized and can be adapted to many systems. However, there is still a need to further enhance and improve their functions to progress their use in the biomedical field. A promising solution is to modify the polymer surfaces with peptides that can increase biocompatibility, cellular interactions, and receptor targeting. In recent years, peptide modifications have been used to overcome many challenges to polymer biomaterial development. This review discusses recent progress in developing peptide-modified polymers for therapeutic applications including cell-specific targeting and tissue engineering. Furthermore, we will explore some of the most frequently studied base components of these biomaterials.

20 January 2021 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
JEJacob A. Erstling
Jacob A. Erstling
JHJoshua A. Hinckley
Joshua A. Hinckley
NBNirmalya Bag
Nirmalya Bag
JHJessica Hersh
Jessica Hersh
GFGrant B. Feuer
Grant B. Feuer
UWUlrich B. Wiesner
Ulrich B. Wiesner

15 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJessica Hersh
Jessica Hersh
JCJose Manuel Condor Capcha
Jose Manuel Condor Capcha
CICamila I Irion
Camila I Irion
GLGuerline Lambert
Guerline Lambert
MNMauricio Noguera
Mauricio Noguera
SSSuresh Shrestha
Suresh Shrestha
Gene therapy is a good alternative for determined congenital disorders; however, there are numerous limitations for gene delivery in vivo including targeted cellular uptake, intracellular trafficking, and transport through the nuclear membrane. Here, a modified G5 polyamidoamine (G5 PAMAM) dendrimer–DNA complex was developed, which will allow cell-specific targeting to skeletal muscle cells and transport the DNA through the intracellular machinery and the nuclear membrane. The G5 PAMAM nanocarrier was modified with a skeletal muscle-targeting peptide (SMTP), a DLC8-binding peptide (DBP) for intracellular transport, and a nuclear localization signaling peptide (NLS) for nuclear uptake, and polyplexed with plasmid DNA containing the GFP-tagged microdystrophin (µDys) gene. The delivery of µDys has been considered as a therapeutic modality for patients suffering from a debilitating Duchenne muscular dystrophy (DMD) disorder. The nanocarrier–peptide–DNA polyplexes were prepared with different charge ratios and characterized for stability, size, surface charge, and cytotoxicity. Using the optimized nanocarrier polyplexes, the transfection efficiency in vitro was determined by demonstrating the expression of the GFP and the µDys protein using fluorescence and Western blotting studies, respectively. Protein expression in vivo was determined by injecting an optimal nanocarrier polyplex formulation to Duchenne model mice, mdx4Cv. Ultimately, these nanocarrier polyplexes will allow targeted delivery of the microdystrophin gene to skeletal muscle cells and result in improved muscle function in Duchenne muscular dystrophy patients.

19 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJessica Hersh
Jessica Hersh
YYYu-Ping Yang
Yu-Ping Yang
EREvan Roberts
Evan Roberts
DBDaniel Bilbao
Daniel Bilbao
Wensi TaoWensi Tao
Wensi Tao
SSSuresh Shrestha
Suresh Shrestha
In vivo imaging has enabled impressive advances in biological research, both preclinical and clinical, and researchers have an arsenal of imaging methods available. Bioluminescence imaging is an advantageous method for in vivo studies that allows for the simple acquisition of images with low background signals. Researchers have increasingly been looking for ways to improve bioluminescent imaging for in vivo applications, which we sought to achieve by developing a bioluminescent probe that could specifically target cells of interest. We chose pancreatic ductal adenocarcinoma (PDAC) as the disease model because it is the most common type of pancreatic cancer and has an extremely low survival rate. We targeted the epidermal growth factor receptor (EGFR), which is frequently overexpressed in pancreatic cancer cells, using an EGFR-specific affibody to selectively identify PDAC cells and delivered a Gaussia luciferase (GLuc) bioluminescent protein for imaging by engineering a fusion protein with both the affibody and the bioluminescent protein. This fusion protein was then complexed with a G5-PAMAM dendrimer nanocarrier. The dendrimer was used to improve the protein stability in vivo and increase signal strength. Our targeted bioluminescent complex had an enhanced uptake into PDAC cells in vitro and localized to PDAC tumors in vivo in pancreatic cancer xenograft mice. The bioluminescent complexes could delineate the tumor shape, identify multiple masses, and locate metastases. Through this work, an EGFR-targeted bioluminescent–dendrimer complex enabled the straightforward identification and imaging of pancreatic cancer cells in vivo in preclinical models. This argues for the targeted nanocarrier-mediated delivery of bioluminescent proteins as a way to improve in vivo bioluminescent imaging.

10 September 2019 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
TGThomas C. Gardinier
Thomas C. Gardinier
MTMelik Z. Turker
Melik Z. Turker
JHJoshua A. Hinckley
Joshua A. Hinckley
WKWilliam P. Katt
William P. Katt
NDNaedum DomNwachukwu
Naedum DomNwachukwu
UWUlrich B. Wiesner
Ulrich B. Wiesner

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
JHJessica Hersh
Jessica Hersh
YYYu-Ping Yang
Yu-Ping Yang
EREvan Roberts
Evan Roberts
DBDaniel Bilbao
Daniel Bilbao
Wensi TaoWensi Tao
Wensi Tao
SSSuresh Shrestha
Suresh Shrestha
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and has a very low survival rate. This cancer often does not show symptoms until more advanced stages, leading to late-stage diagnosis in up to 80% of cases. Molecular tools for accurate identification of the cancer cells can lead to a timely diagnosis. Currently, blood antigen testing with CA 19-9 and tumor imaging using ultrasound, CT, and MRI are the standards for identification. However, these methods are limited in their ability to discern key attributes such as tumor localization, grading, and metastasis. To overcome this, we can utilize selective recognition of PDAC markers to deliver a bioluminescent protein for targeted imaging. We applied dendrimers as a nanocarrier that can hold both the PDAC-targeting protein and the bioluminescent protein for enhancement of blood-circulation and tumor-retention time, thereby producing a stronger, longer lasting luminescent signal. This cell-specific recognition assembly can locate both localized and metastatic PDAC cells, enabling an accurate diagnosis, localization of tumor margin, and identification of metastases using bioluminescence-based imaging. The targeted construct was formed by fusing an EGFR-specific affibody to Gaussia luciferase, a bioluminescent protein, and binding that to a G5 polyamidoamine dendrimer nanocarrier. Western Blotting and confocal microscopy using PANC 10.05 cells confirmed the expression of EGFR and enhanced uptake of the targeted construct in vitro. For in vivo studies, female NSG mice were used as a xenograft model with PANC 10.05 cells with either subcutaneous, renal capsule, or orthotopic tumors. Tumor-bearing mice were treated with dendrimer-fusion protein constructs and imaged using IVIS. Controls included non-targeted bioluminescent proteins and non-tumor-bearing mice. The presence of EGFR on the tumors of implanted mice was confirmed using Western blotting and histological staining. We showed that the EGFR-targeted construct was capable of facilitating selective uptake into the tumors in all three mouse models, demonstrating that the cell-specific construct could localize to the PDAC cells and emit bioluminescence when imaged with IVIS. Accuracy of the tumor localization was also confirmed with ultrasound. Additionally, we demonstrated the ability of the construct to locate metastases using both live-animal imaging and ex vivo organ analysis. These bioluminescent nanocarriers are capable of PDAC cell-specific recognition and can be used to locate and image PDAC cells. This methodology can then be applied to mice without confirmed tumors to demonstrate the ability to achieve timely diagnosis for early detection of PDAC. Ultimately, this construct can aid in the identification and localization of PDAC. Citation Format: Jessica Hersh, Yu-Ping Yang, Evan Roberts, Daniel Bilbao, Wensi Tao, Sylvia Daunert, Sapna Deo. Targeted dendrimer nanocarrier delivery of bioluminescent proteins for pancreatic cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2471.